Emerging Isotopes Pipeline Analysis and Global Market

Emerging Isotopes Pipeline Analysis and Global Market - Forecast to 2029

Publication ID:

IQ40814001

Publication Date:

July 12, 2022

Pages:

234

Publisher:

IQ4I

Countries:

Global [1]

USD 4,950.00

Pharma & Healthcare [2]

Drug Pipeline [3]

Research & Development (Pharma & Healthcare) [4]

Description:

鈥淓merging Isotopes Pipeline Analysis and Global Market 鈥� Forecast to 2029鈥� gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).

In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.

Market Analysis
- In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
- Emerging Isotopes related deals analysis.
- Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
Pipeline Analysis
- Pipeline Analysis based Isotopes
- Pipeline Analysis based on indications
- Pipeline analysis based on targets
- Pipeline analysis based on leading players
Key Players Analysis
- The key player鈥檚 analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
- Key players overview
- Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
- Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)

Table Of Contents:

1 EXECUTIVE SUMMARY

2 INTRODUCTION

2.1 REPORT SCOPE
2.2 REPORT DESCRIPTION
2.3 PIPELINE ANALYSIS
2.4 KEY PLAYERS ANALYSIS
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY

3 EMERGING ISOTOPES

3.1 INTRODUCTION
3.2 PIPELINE ANALYSIS OVERVIEW
听听3.2.1 DIAGNOSTIC ISOTOPES PIPELINE ANALYSIS
听听3.2.2 THERAPEUTIC ISOTOPES PIPELINE ANALYSIS
3.3 DEMAND ANALYSIS OF EMERGING ISOTOPES
3.4 LUTETIUM (Lu-177)
听听3.4.1 GEP-NET MARKET ANALYSIS
听听3.4.2 PROSTATE CANCER MARKET ANALYSIS
听听3.4.3 LUTETIUM PIPELINE ANALYSIS
听听听听3.4.3.1 Demand and Production Analysis of Lutetium-177 (Lu-177)
听听3.4.4 Lu-177 鈥� DEALS, APPROVALS, AND FUNDING
3.5 GALLIUM (Ga-68)
听听3.5.1 SUPPLY CHAIN ANALYSIS OF GALLIUM-68 (Ga-68)
听听3.5.2 Ga-68 MARKET
听听3.5.3 GALLIUM-68 (Ga-68) PIPELINE ANALYSIS
听听3.5.4 Ga-68 鈥� DEALS, APPROVALS, AND FUNDING
3.6 ACTINIUM (Ac-225)
听听3.6.1 PRODUCTION ANALYSIS OF ACTINIUM-225 (Ac-225) AND BISMUTH-213 (Bi-213)
听听3.6.2 ACTINIUM (Ac-225) PIPELINE ANALYSIS
听听3.6.3 Ac-225 鈥� DEALS, APPROVALS, AND FUNDING
3.7 YTTRIUM (Y-90)
听听3.7.1 YTTRIUM (Y-90) PIPELINE ANALYSIS
听听3.7.2 Y-90 鈥� DEALS, APPROVALS, AND FUNDING
3.8 ZIRCONIUM (Zr-89)
听听3.8.1 ZIRCONIUM (Zr-89) PIPELINE ANALYSIS
听听3.8.2 Zr-89 鈥� DEALS, APPROVALS, AND FUNDING
3.9 LEAD (Pb-212)/BISMUTH (Bi-212)
听听3.9.1 LEAD (Pb-212) PIPELINE ANALYSIS
听听3.9.2 Pb-212 鈥� DEALS, APPROVALS, AND FUNDING
3.10 COPPER (Cu-64)
听听3.10.1 COPPER 64 (Cu-64) PIPELINE ANALYSIS
听听3.10.2 Cu-64 鈥� DEALS, APPROVALS, AND FUNDING
3.11 COPPER (Cu-67)
听听3.11.1 COPPER 67 (Cu-67) PIPELINE ANALYSIS
听听3.11.2 Cu-67 鈥� DEALS, APPROVALS, NEWS, AND FUNDING
3.12 RHENIUM (Re-186)
听听3.12.1 RHENIUM (Re-186) PIPELINE ANALYSIS
听听3.12.2 Re-186 鈥� DEALS, APPROVALS, NEWS, AND FUNDING
3.13 RHENIUM-188 (Re-188)
听听3.13.1 RHENIUM (Re-188) PIPELINE ANALYSIS
听听3.13.2 Re-188 鈥� DEALS, APPROVALS, NEWS, AND FUNDING
3.14 ASTATINE (At-211)
听听3.14.1 ASTATINE (At-211) PIPELINE ANALYSIS
听听3.14.2 At-211 鈥� DEALS, APPROVALS, NEWS, AND FUNDING
3.15 HOLMIUM (Ho-166)
听听3.15.1 HOLMIUM (Ho-166) PIPELINE ANALYSIS
听听3.15.2 Ho-166 鈥� DEALS, APPROVALS, AND NEWS
3.16 RADIUM (Ra-223)
听听3.16.1 SUPPLY CHAIN ANALYSIS OF RADIUM-223 (Ra-223)
听听3.16.2 RADIUM (Ra-223) PIPELINE ANALYSIS
3.17 RADIUM (Ra-224)
听听3.17.1 RADIUM (Ra-224) PIPELINE ANALYSIS
听听3.17.2 Ra-224 鈥� DEALS, APPROVALS, NEWS, AND FUNDING
3.18 THORIUM (Th-227)
听听3.18.1 THORIUM (Th-227) PIPELINE ANALYSIS
3.19 SCANDIUM (Sc-43, 44, 47)
3.20 TERBIUM (Tb-149,152,155, 161)
3.21 ARSENIC (As-72, As-74, As-77)
3.22 IRON (Fe-52)
3.23 BARIUM-128 (Ba-128)
3.24 BARIUM-131 (Ba-131)

4 MAJOR PLAYER PROFILES

4.1 BOSTON SCIENTIFIC CORPORATION (BSC)
4.2 CLARITY PHARMACEUTICALS LIMITED
4.3 CURIUM SAS
4.4 ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG (PENTIXAPHARM, GMBH)
4.5 FUSION PHARMACEUTICALS, INC.
4.6 ITM ISOTOPE TECHNOLOGIES MUNICH SE
4.7 NOVARTIS AG
4.8 ORANO MED, LLC
4.9 PLUS THEAPEUTICS, INC.
4.10 POINT BIOPHARMA GLOBAL, INC.,
4.11 RADIOMEDIX, INC.,
4.12 TELIX PHARMACEUTICALS, LTD.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂